施贵宝公司10月31日盘中大涨5.04%,主要受到该公司公布的第三季度财报好于预期的利好消息带动。
施贵宝第三季度盈利37亿美元,每股收益1.8美元,均超过了分析师预期。营收达到118.9亿美元,同比增长8%,也高于分析师预期的112.8亿美元。公司业绩大幅超预期,主要得益于旗舰产品Eliquis和Revlimid等老药销售持续强劲,以及新上市心脏治疗药Camzyos和免疫疗法Breyanzi等新药实现爆发式增长。
基于出色的第三季度业绩表现,施贵宝上调了全年盈利预期,预计全年每股收益将达到75至95美分,较之前预期60至90美分有所提高。这一积极预期也进一步提振了市场对公司未来增长前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.